Victory Capital Management
PVLA

Victory Capital Management’s Palvella Therapeutics PVLA Stock Holding History

Victory Capital Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.76M Buy
11,531
+128
+1% +$15.5K ﹤0.01% 1665
2026
Q1 		$1.42M Sell
11,403
-2,721
-19% -$284K ﹤0.01% 1706
2025
Q4 		$1.48M Buy
+14,124
New +$1.2M ﹤0.01% 1659
2020
Q2 		– Sell
-112
Closed -$20K – 3340
2020
Q1 		$20K Buy
+112
New +$28.2K ﹤0.01% 2847
2019
Q4 		– Sell
-93
Closed -$25K – 3330
2019
Q3 		$25K Buy
+93
New +$36K ﹤0.01% 2967

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Victory Capital Management's PVLA Position: Q2 2026 in Review

Victory Capital Management increased its Palvella Therapeutics (PVLA) stake by 1.1% in Q2 2026, buying an estimated $15.5K and bringing the position to 11,531 shares worth $1.76M. The position accounts for ﹤0.01% of the portfolio, ranked #1665.

Victory Capital Management first reported a position in PVLA in Q3 2019 and has held it in 5 quarters since. 196 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • Victory Capital Management held 11,531 shares of Palvella Therapeutics worth $1.76M as of Q2 2026.
  • Victory Capital Management bought 128 Palvella Therapeutics shares in Q2 2026, an estimated $15.5K.
  • Palvella Therapeutics made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #1665 holding.
  • Victory Capital Management first reported a position in Palvella Therapeutics in Q3 2019 and has held it in 5 quarters since.
  • 196 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.